NCT02220218View on ClinicalTrials.gov

Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Healthy
Interventions
DRUG

Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)

Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

DRUG

Canagliflozin

Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

DRUG

Metformin IR

Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.

Trial Locations (1)

Unknown

Lincoln

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02220218 - Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants | Biotech Hunter | Biotech Hunter